Basic Information
LncRNA/CircRNA Name | NORAD |
Synonyms | NA |
Region | GRCh38_20:36045622-36050960 |
Ensemble | ENSG00000260032 |
Refseq | NR_027451 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | 2 | ||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | epithelial ovarian cancer |
ICD-0-3 | C56.9 |
Methods | qPCR, Luciferase reporter assay, in vitro knockdown |
Sample | An immortal normal human ovarian epithelial cell line, HS832.Tc, and seven human EOC cell lines, SK-OV-3, CAOV-3, CAOV-4, OVCAR-3, HEY-T30, ES-2, and SW/626, EOC tumor samples and paired adjacent non-tumor samples |
Expression Pattern | up-regulated |
Function Description | NORAD was substantially upregulated in both EOC cell lines and human tumors. In OVCAR-3 and ES-2 cells, lentivirus-mediated NORAD downregulation had significant anticancer effects, as it suppressed cell proliferation, decreased bufalin chemoresistance, arrested cell-cycle transition, and inhibited xenograft growth. Also, hsa-miR-155-5p was confirmed to be the competing target of NORAD in EOC, and its knockdown in OVCAR-3 and ES-2 cells reversed the NORAD downregulation-induced anticancer functions |
Pubmed ID | 31250987 |
Year | 2019 |
Title | Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p |
External Links
Links for NORAD | GenBank HGNC NONCODE |
Links for epithelial ovarian cancer | OMIM COSMIC |